"Hope for Diabetes: Sana Biotech's Island Cell Therapy Boosts Stocks by 150% After Hours"

Sana Biotechnology's shares surged 150% in after-hours trading on Tuesday following preliminary results from a new clinical trial that could have significant implications for the treatment of type 1 diabetes. Conducted in collaboration with Uppsala University Hospital, the study tested the company's engineered islet cell therapy, UP421, in a patient with type 1 diabetes without the use of immunosuppressive drugs.

Initial findings observed four weeks post-transplant indicated that the transplanted pancreatic beta cells survived and functioned. This was evidenced by the detectability of C-peptide levels, which are an indicator of insulin production. Notably, the study reported no adverse safety issues, and MRI scans confirmed the continued presence of the transplanted cells, suggesting that the cells successfully evaded the body's immune response.